Skip to content Skip to sidebar Skip to footer

Apellis attempts to clear the air around Syfovre safety as eye drug launch gains steam


For Apellis Pharmaceuticals, the emergence of rare but serious side effects has cast a pall over the launch of the company’s geographic atrophy med Syfovre. | While touting the “strong commercial execution” of Syfovre’s launch, Apellis’ CEO Cedric Francois, M.D., Ph.D., admitted the company has become aware of several cases of retinal vasculitis tied to the drug’s use.


Leave a comment